We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

The Value of Pharmacogenetic Testing

Alan G. Pocinki, MD, PLLC1
[+] Author Affiliations
1George Washington University, Washington, DC
JAMA Intern Med. 2015;175(2):314. doi:10.1001/jamainternmed.2014.7017.
Text Size: A A A
Published online


To the Editor In their August 2014 editorial, “Warfarin, Genes, and the (Health Care) Environment,” Kazi and Hlatky1 point out a number of plausible reasons why pharmacogenetic data in this setting did not make a significant difference in the clinical outcomes measured. They then argue that effects on “surrogate markers, such as drug levels” are insufficient to recommend widespread pharmacogenetic testing, yet such testing, like any diagnostic testing, should not be performed in a “widespread” way but only when clinically indicated.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





February 1, 2015
Dhruv S. Kazi, MD, MSc, MS; Mark A. Hlatky, MD
1Department of Medicine (Cardiology), University of California, San Francisco2Department of Epidemiology and Biostatistics, University of California, San Francisco
3Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California4Department of Medicine, Stanford University School of Medicine, Stanford, California
JAMA Intern Med. 2015;175(2):314-315. doi:10.1001/jamainternmed.2014.7023.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...